Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease

Journal of Neural Transmission

Volumn 116, Issue 9, 2009, Pages 1079-1086

  Vamos, Eniko ^a   Voros, Krisztina ^a   Zadori, Denes ^a   Vecsei, Laszlo ^a   Klivenyi, Peter ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Huntington's disease; Kynurenic acid; Neuroprotection; Probenecid

Indexed keywords

PROBENECID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL AGGREGATION; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT; MOTOR ACTIVITY; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC ANIMAL;

AGE FACTORS; ANIMALS; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HUMANS; HUNTINGTON DISEASE; KAPLAN-MEIERS ESTIMATE; KYNURENIC ACID; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PROBENECID; STATISTICS, NONPARAMETRIC; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 69549114430     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0253-6     Document Type: Article

References (37)

1. OR Adam J Jankovic 2008 Symptomatic treatment of Huntington disease Neurotherapeutics 5 181 197
2. MF Beal WR Matson KJ Swartz PH Gamache ED Bird 1990 Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid J Neurochem 55 1327 1339
3. MF Beal WR Matson E Storey P Milbury EA Ryan T Ogawa ED Bird 1992 Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex J Neurol Sci 108 80 87
4. DW Choi 1988 Alzheimer's disease and dementia Med Sect Proc 12 9 155
5. SP Cole G Bhardwaj JH Gerlach JE Mackie CE Grant KC Almquist AJ Stewart EU Kurz AM Duncan RG Deeley 1992 Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1650 1654
6. JH Connick V Carla F Moroni TW Stone 1989 Increase in kynurenic acid in Huntington's disease motor cortex J Neurochem 52 985 987
7. M DiFiglia E Sapp KO Chase SW Davies GP Bates JP Vonsattel N Aronin 1997 Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1990 1993
8. G Gardian L Vecsei 2004 Huntington's disease: pathomechanism and therapeutic perspectives J Neural Transm 111 1485 1494
9. PM Gerk M Vore 2002 Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition J Pharmacol Exp Ther 302 407 415
10. CA Gutekunst SH Li H Yi JS Mulroy S Kuemmerle R Jones D Rye RJ Ferrante SM Hersch XJ Li 1999 Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J Neurosci 19 2522 2534
11. C Hilmas EF Pereira M Alkondon A Rassoulpour R Schwarcz EX Albuquerque 2001 The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications J Neurosci 21 7463 7473
12. PF Juranka RL Zastawny V Ling 1989 P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins FASEB J 3 2583 2592
13. A Lazarowski L Caltana A Merelli MD Rubio AJ Ramos A Brusco 2007 Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci 258 84 92
14. G Lee R Bendayan 2004 Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders Pharm Res 21 1313 1330
15. ZP Lin YL Zhu DR Johnson KP Rice T Nottoli BC Hains J McGrath SG Waxman AC Sartorelli 2008 Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response Mol Pharmacol 73 243 251
16. L Mangiarini K Sathasivam M Seller B Cozens A Harper C Hetherington M Lawton Y Trottier H Lehrach SW Davies GP Bates 1996 Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 493 506
17. AF Miranda RJ Boegman RJ Beninger K Jhamandas 1997 Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid Neuroscience 78 967 975
18. F Moroni P Russi G Lombardi M Beni V Carla 1988 Presence of kynurenic acid in the mammalian brain J Neurochem 51 177 180
19. V Perez-De La Cruz A Santamaria 2007 Integrative hypothesis for Huntington's disease: a brief review of experimental evidence Physiol Res 56 513 526
20. H Potschka M Fedrowitz W Loscher 2003 Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity J Pharmacol Exp Ther 306 124 131
21. C Prescott AM Weeks KJ Staley KM Partin 2006 Kynurenic acid has a dual action on AMPA receptor responses Neurosci Lett 402 108 112
22. S Rapposelli M Digiacomo A Balsamo 2009 P-gp transporter and its role in neurodegenerative diseases Curr Top Med Chem 9 209 217
23. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100:9244-9249
24. GP Reynolds SJ Pearson 1992 Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes J Neurol Sci 113 230 233
25. SM Rothman JW Olney 1986 Glutamate and the pathophysiology of hypoxic-ischemic brain damage Ann Neurol 19 105 111
26. A Santamaria C Rios F Solis-Hernandez J Ordaz-Moreno L Gonzalez-Reynoso M Altagracia J Kravzov 1996 Systemic dl-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats Neuropharmacology 35 23 28
27. MT Sapko P Guidetti P Yu DA Tagle R Pellicciari R Schwarcz 2006 Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease Exp Neurol 197 31 40
28. GL Scheffer RJ Scheper 2002 Drug resistance molecules: lessons from oncology Novartis Found Symp 243 19 31
29. G Schilling MW Becher AH Sharp HA Jinnah K Duan JA Kotzuk HH Slunt T Ratovitski JK Cooper NA Jenkins NG Copeland DL Price CA Ross DR Borchelt 1999 Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin Hum Mol Genet 8 397 407
30. R Schwarcz CA Tamminga R Kurlan I Shoulson 1988 Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia Ann Neurol 24 580 582 (Pubitemid 18236504)
31. WR Silverman VJP De Rivero S Locovei F Qiu SK Carlsson E Scemes RW Keane G Dahl 2009 The pannexin 1 channel activates the inflammasome in neurons and astrocytes J Biol Chem 10.1074/jbc.M109.004804
32. DL Smith R Portier B Woodman E Hockly A Mahal WE Klunk XJ Li E Wanker KD Murray GP Bates 2001 Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles Neurobiol Dis 8 1017 1026
33. TW Stone 1993 Neuropharmacology of quinolinic and kynurenic acids Pharmacol Rev 45 309 379
34. M Tanaka Y Machida S Niu T Ikeda NR Jana H Doi M Kurosawa M Nekooki N Nukina 2004 Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease Nat Med 10 148 154
35. The Huntington's Disease Collaborative Research Group 1993 A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 971 983
36. J Urenjak TP Obrenovitch E Zilkha 1997 Effect of probenecid on depolarizations evoked by N-methyl-d-aspartate (NMDA) in the rat striatum Naunyn Schmiedebergs Arch Pharmacol 355 36 42 (Pubitemid 27008450)
37. J Wang N Simonavicius X Wu G Swaminath J Reagan H Tian L Ling 2006 Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35 J Biol Chem 281 22021 22028